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plantation, Cassaday et al. report improved survival rates in
patients with indolent B cell lymphomas who underwent
antieCD-20 radioimmunotherapy (RIT) using yttrium-90-
ibrutinib tiuxetan (90YIT) (Zevalin; Spectrum Pharmaceuti-
cals, Henderson, NV) with their nonmyeloablative trans-
plantation conditioning regimen [1]. All of these patients had
been exposed to rituximab. The authors compared their re-
sults to those of a historical control group of patients who did
not receive 90YIT [1]. After adjusting for imbalances in pa-
tients’ characteristics, including chemoresistant and bulky
disease, thrombocytopenia, and hematopoietic cell trans-
plant comorbidity index scores of  3, favoring the control
group, the 3-year adjusted estimates of overall survival and
progression-free survival in the 90YIT group were 87% and
71% versus 59% and 44%, respectively, in the non-90YIT group.
The authors acknowledge the limitation of the small
number of patients studied (n¼ 18), which was even smaller
after adjusting for high-risk disease features described
above. Nevertheless, their ﬁndings further conﬁrm that RIT
improves the outcome of patients with relapsed or refractory
high-risk indolent lymphoma who have been considered for
nonmyeloablative allogeneic transplantation. They are also
in agreement with those of an earlier report from our center
of a 3-year progression-free survival rate of 80% in refractory
follicular lymphoma patients after allogeneic transplantation
and 90YIT [2].DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.10.024.
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http://dx.doi.org/10.1016/j.bbmt.2014.12.011Nonmyeloablative conditioning has been the cornerstone
of adoptive allogeneic immunotherapy for B cell indolent
lymphoma that has failed to respond to conventional treat-
ment. Pretransplantation chemosensitivity versus refracto-
riness has been an important determinant of outcomes [3],
and how to treat refractory disease without inducing addi-
tional toxicity has been a challenge. One strategy to enhance
initial disease control is to incorporate novel agents into
allogeneic conditioning regimens that are effective against
lymphoma; remission can later be sustained via the graft-
versus-lymphoma effect. One of the most compelling of
these agents is 90YIT, which is used as targeted therapy in
indolent lymphomas.
The known sensitivity of B cell indolent lymphomas to
conventional radiotherapymakes them an attractive target for
RIT. In the United States, 90YIT has been approved for the
treatment of relapsed low-grade and follicular lymphomas. In
2009, the drug received an additional indication for use as
consolidation after initial chemotherapy [4]. 90YIT uses the
antibody to mediate complement-mediated cytotoxicity,
along with the delivery of high-energy, short path length
(5 mm) beta irradiation from 90Y to both CD20-lymphoma
cells and neighboring tumor cells that are inaccessible to the
antibody or have insufﬁcient antigen expression as a result of
a cross-ﬁre effect, with little effect on other solid organs.
Of note, positive resultswere found in this study inpatients
with chronic lymphocytic leukemia (CLL)/small lymphocytic
lymphoma (10 of 18 patients), whereas the degree of marrow
involvement and cytopenia were not factored into eligibility
criteria to receive 90YIT. RIT is not known to be active as a single
agent, without transplantation, in these histologic types. In a
study at MD Anderson, 90YIT was administered to 14 patients
with relapsed CLL that was in partial (but with <25% marrow
involvement) or complete remission but with persistent min-
imal residual disease after chemotherapy [5]. Patients were
required to have a platelet count of >100,000/mm3. Of the 13
patients evaluable for response, only 1 patient achieved an
minimal residual diseaseenegative remission but soon there-
after had Richter transformation. Grade 3 hematological
toxicity was seen in 12 of the 13 evaluable patients. In view of
this contrast in responses and safety, further exploration is
D.H. Vesole, D.S. Siegel / Biol Blood Marrow Transplant 21 (2015) 199e201200needed of themechanismof action of 90YIT in these diseases in
the context of allogeneic transplantation.
How can the information in the Cassaday et al. study be
used in clinical practice? The results of the current study
conﬁrm that the type of conditioning used in non-
myeloablative transplantation strategies matters and that 1
size does not ﬁt all. The results of this study and the study at
our center suggest that 90YIT should be more frequently
administered to patients with active or refractory indolent
lymphoma before transplantation. However, patients should
be treated in clinical trials. The CLL results are intriguing and
need to be conﬁrmed in other studies. Contrary to previous
ﬁndings in mouse models [6], it appears that prior exposure
to rituximab does not affect the efﬁcacy or safety of trans-
plantation with 90YIT.
Finally, this study does not address the lingering question
in allogeneic transplantation: the incidence of graft-versus-
host disease (GVHD). Over 70% of patients in this study
developed acute II to IV GVHD. This incidence appears to be
higher (23%) than observed in our transplantation studywith
90YIT [2], suggesting that the difference is related to the
GVHD prophylaxis used rather than to the innate condi-
tioning regimen. In this era of novel B cell receptor path-
wayetargeted agents, such as ibrutinib and idelalisib, it is
paramount that the safety of allogeneic transplantation be
enhanced to encourage referrals from the community.DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.10.023.
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Marrow Transplant Research (CIBMTR) report a retrospective
database analysis of pretransplant depth of response and its
impact on transplant outcomes. This article addresses some
of the most complex problems facing not only transplanters
but the greater myeloma community as well. Should we
optimize pretransplant induction regimens to improve post-
transplant remission duration and survival? A growing
number of studies indicate that the depth of response pre-
transplant correlates with post-transplant progression-free
survival (PFS) and, in some studies, overall survival (OS) [2,3].
With the advent of technologies allowing the assessment of
progressively lower burdens of disease, these correlations
between depth of response and PFS and OS have become
more profound and with this the inclination to intensify
therapy to lessen the extent of minimal residual disease(MRD) more compelling. More and more clinical trials are
being designed in which patients with detectable MRD after
the completion of therapy are shifted to alternative, often
more intense regimens to eliminate the last vestiges of MRD.
However, we have never deﬁnitively answered the question
if doing more to achieve a greater depth of response, at the
expenses of increased toxicity, impairment of quality of life,
and potential loss of future treatment options, ultimately
translates into improved outcomes. Prior studies do not
address whether induction algorithms should include mul-
tiple regimens to achieve a greater response depth. Indeed,
this is not limited to induction therapy but is pertinent to all
myeloma care, including post-transplant consolidation and
maintenance.
Thus, important questions are generated: How many
cycles of induction therapy should we administer? Should
we treat to maximum response with 1 induction regimen?
Or, should we treat with sequential induction regimens
until we achieve a “good” response? Additional pretrans-
plant issues must be addressed, as they pertain to pre-
transplant depth of response. Three stem cell mobilization
strategiesdgrowth factor(s) alone, mobilizing chemo-
therapy that is not cytoreductive, and mobilizing regimensd
are both cytoreductive and good mobilizers. The latter,
obviously, also may improve the depth of response. If the
overall goal is pretransplant response depth, then stem cell
mobilization strategies should include cytoreductive mobi-
lization regimens.
